Operating Company Healthcare

X-Chem

Waltham, Massachusetts, United States

X-Chem is a small-molecule discovery partner that combines DNA-encoded library (DEL) technology, discovery chemistry, and artificial intelligence (including its ArtemisAI platform) to support biopharma programs from screen-to-hit through hit-to-lead and lead optimization / candidate identification.

Focus Areas
DNA-encoded libraries (DEL), Artificial intelligence for drug discovery, Medicinal chemistry

Tracked deals

3

3 tracked deals across 2021.

Recent pace

0

0 tracked deals announced in the last 12 months.

Deal mix

Addon

2 addon · 1 buyout

X-Chem Acquisition Volume by Year

Last 1 years

Acquisition volume by year Annual acquisition counts for the last 1 years for X-Chem. 3 2021

Supporting Data

Recent Transactions

  • X-Chem Acquires Glamorous AI and ComInnex
    October 29, 2021
    Buyer
    X-Chem
    Target
    Glamorous AI, ComInnex
    Industry
    Biotechnology
    Location
    Hungary
    Type
    Addon

    X-Chem, a GHO Capital-backed leader in DNA-encoded library (DEL) technology, has acquired AI drug-discovery specialist Glamorous AI and Budapest-based synthetic chemistry services provider ComInnex. The deals expand X-Chem’s machine-learning capabilities and synthetic chemistry capacity, broadening its global footprint and accelerating small-molecule discovery services for biopharma clients.

  • X-Chem Acquires Glamorous AI
    October 28, 2021
    Buyer
    X-Chem, Inc.
    Target
    Glamorous AI
    Industry
    Biotechnology
    Location
    England, United Kingdom
    Type
    Buyout

    X-Chem, a leader in DNA-encoded library (DEL) technology, has acquired Glamorous AI, an AI-driven drug discovery software provider. The deal combines X-Chem's large DEL datasets with Glamorous AI's RosalindAI platform to accelerate early-stage small-molecule drug discovery and expand X-Chem's machine-learning capabilities.

  • X-Chem Acquires IntelliSyn and AviSyn to Expand Drug Discovery Services
    January 26, 2021
    Buyer
    X-Chem, Inc.
    Target
    IntelliSyn, AviSyn
    Seller
    Shareholders of IntelliSyn and AviSyn
    Industry
    Biotechnology
    Location
    Quebec, Canada
    Type
    Addon

    X-Chem, a portfolio company of GHO Capital, has acquired Montreal-based IntelliSyn and its US-based sister company AviSyn to extend its drug discovery offering into medicinal chemistry, custom synthesis and scale-up process chemistry. The deal integrates downstream hit validation and lead optimisation capabilities into X-Chem’s DNA-Encoded Library (DEL) platform, enabling a streamlined screen-to-lead service for pharma and biotech clients; financial terms were not disclosed.

Related Acquisition Pages

Biotechnology Buyers & Acquisitions 3 tracked deals by X-Chem.

Related articles

Selling a company? Get in front of buyers like X-Chem

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →